«This study shows that researchers working on problems in rare diseases, such as blood pressure
in synucleinopathies, can pool together data and ideas and develop a simple bedside test that can perhaps help spot these problems earlier,» says Dr. Kaufmann, the Felicia B. Axelrod Professor of Dysautonomia Research in the Department of Neurology, and professor of medicine and pediatrics at NYU School of Medicine.
Not exact matches
Overall, patients with
synucleinopathies died about two years earlier than participants without
in the comparison group.
A new article published by JAMA Neurology compares survival rates among patients with
synucleinopathies, including Parkinson disease, dementia with Lewy bodies, Parkinson disease dementia and multiple system atrophy with parkinsonism, with individuals
in the general population.
Although several large studies have shown that α - synuclein levels are lower
in the CSF of PD patients and those with related
synucleinopathies compared to controls, its role
in cognitive decline and dementia had been unexplored.
Yet if you look at people who develop the clinical syndrome of dementia, especially later
in life, yes, they have amyloid
in the brain but they also have other pathologic entities — vascular disease;
synucleinopathies [insoluble fibrils of the normally soluble protein, alpha - synuclein]; a tauopathy [which is marked by disease - inducing, insoluble tangles of another protein, tau].
Lewy bodies (LB) and other intracellular α - synuclein (AS) aggregates accumulate
in the aging nervous system, and a high burden of such aggregates are hallmark neuropathological signs of Parkinson's disease (PD), Lewy body dementia (LBD), multiple systems atrophy (MSA), and other
synucleinopathies.
In the ensuing months, the two companies have published detailed, promising animal studies of their immunotherapies, including preclinical efficacy studies in animal models of human synucleinopathie
In the ensuing months, the two companies have published detailed, promising animal studies of their immunotherapies, including preclinical efficacy studies
in animal models of human synucleinopathie
in animal models of human
synucleinopathies.
Meanwhile, the European Union - funded SYMPATH Project has received nearly $ 6 million from the Seventh Framework Program to test AFFiRiS» AS - targeting vaccines
in patients suffering with
synucleinopathies.
The clinical consortium is led by AFFiRiS itself, and
in addition to the PD booster trial, it is now recruiting for a separate Phase I trial of the α - synuclein vaccine against MSA, a
synucleinopathy differentiated from PD or LBD based on the cell populations affected, the regional concentration of AS neuropathology, and the spectrum of movement and other symptoms.
As recently as two years ago, there was little evidence of any academic or biotech industry interest
in pursuing clearance of AS as a therapeutic approach to PD, LBD, or other
synucleinopathies of aging: after a promising 2005 report, [31] there had been virtual silence.
AFF 1: Preclinical Efficacy Data AFF 1 was then tested for preclinical efficacy
in two models of human
synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to LBD than PD.
His research interests include cellular lipid and protein degradation systems — and their malfunction —
in relation to Parkinson's disease and other
synucleinopathies.
The company's antibody - based product candidates target a number of potential indications including AL and AA forms of amyloidosis, Parkinson's disease and other related
synucleinopathies and novel cell adhesion targets involved
in inflammatory diseases and cancers.